Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.

Onco Targets Ther · 2014 · PMC4240193 · PMID 25484594

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

35 Concerning clinical outcome, patients with TOP2A positivity showed a trend to develop fewer recurrences and to have a prolonged disease-free survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.